hCAI/II-IN-4 

hCAI/II-IN-4 (compound 6d) is a potent dual hCA I/II inhibitor with K_i values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research^[1].

K_i:16.95 nM (hCA I)、15.22 nM (hCA II) and 27.04 nM (hCA Ⅸ)

hCAI/II-IN-4 (compound 6d) (5-200μM; 48 hours) has no apparent cytotoxicity in HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

hCAI/II-IN-4 (compound 6d) (400-2000 mg/kg; p.o.; Male BLAB/c mice of hypoxia) has no apparent toxic effect in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

381.43

C₁₅H₁₅N₃O₅S₂

2480284-01-1

O=C(C1=CSC(NC(C2=CC=C(S(=O)(N)=O)C=C2)=O)=N1)OCC3CC3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang C, et al. N-Quinary heterocycle-4-sulphamoylbenzamides exert anti-hypoxic effects as dual inhibitors of carbonic anhydrases I/II. Bioorg Chem. 2020 Jul;100:103931.  [Content Brief]